SELFDIAGNOSTICS MULTITEST COVID-19
Molecular Diagnostics Multitest Platform by Selfdiagnostics
So far, rapid tests have needed confirmatory laboratory tests. For the first time in history, molecular rapid tests enable diagnosis confirmation without the need of repeated laboratory tests, giving doctors the possibility to start treatment immediately.
Selfdiagnostics Multitest COVID-19 – a rapid molecular NAAT test – combines the ease of use of rapid tests and the diagnosis accuracy of laboratory PCR tests. It really is like having a rapid PCR test in your pocket.
Selfdiagnostics Multitest COVID-19 is a good fit for any setting like:
Intentionally simple and with minimal component design for cost efficient mass production. Modular production lines enable fast production scale-up.
Able to differentiate up to four different organism’s RNA or DNA from one sample in a single run. Duplex panel test – Selfdiagnostics STD Multitest CT/NG is also in our portfolio.
Proven multi-sample capability. Tests from swab and urine samples are ready. Expandable to detect from blood, soil and water samples.
ENGINEERED AND MANUFACTURED IN GERMANY
Multiplex Platform and Tests are developed and manufactured in Germany.
Selfdiagnostics has access to top European virology labs for continuous R&D and validation. Thanks to partnerships with Fraunhofer Institute for Cell Therapy and Immunology (IZI), Dresden University of Technology, TalTech and University of Tartu. And together with the Saxonian Development Bank (SAB), Selfdiagnostics aims to fulfil the German Government order to develop and manufacture innovative testing technologies.
CE IVDR AND FDA CLEARANCE
Following first commercial availability under CE Mark in selected markets, Selfdiagnostics plans CE IVDR and FDA clearance for Selfdiagnostics Multitest COVID-19 and Multitest CT/NG in other global markets throughout 2022.